Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Lessons learned from the implementation of non-invasive fetal RHD screening

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. IP-10 release assays in the diagnosis of tuberculosis infection: current status and future directions

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Targeted Rhesus immunoglobulin for RhD negative women undergoing an induced abortion: a clinical pilot study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Blood group genotyping of blood donors: validation of a highly accurate routine method

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Noninvasive fetal RHD genotyping to guide targeted anti-D prophylaxis-an external quality assessment workshop

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Noninvasive Antenatal Screening for Fetal RHD in RhD Negative Women to Guide Targeted Anti-D Prophylaxis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

INTRODUCTION: In the fight against hemolytic disease of the fetus and newborn, pregnant RhD negative women are offered antenatal and postnatal anti-D immunoglobulin prophylaxis to prevent the development of antibodies against the fetal D antigen. Antenatal prophylaxis has traditionally been provided to all D negative pregnant women, as the fetal RhD type remains unknown until birth. With noninvasive prenatal testing of cell-free DNA, predicting the fetal RhD type has become highly feasible based on analysis of the fetal RHD gene. Fetal RHD screening can guide targeted antenatal prophylaxis, treating only women who carry an RhD positive fetus, thereby avoiding the unnecessary treatment of approximately 40% of the RhD negative women. Areas covered: Areas covered are the current clinical practice, performance, and challenges of fetal RHD screening, and relevant issues for its implementation. Expert commentary: Fetal RHD screening is highly accurate, with sensitivities of 99.9%, as reported from clinical programs. From gestational week 10, sensitivities are approximately 99%. Despite challenges in assay design, low levels of cell-free fetal DNA in the maternal plasma, and concerns regarding implementation and medical necessity, the clinical experience with fetal RHD screening and targeted prophylaxis has generated encouraging results, and its future widespread use is expected.

OriginalsprogEngelsk
TidsskriftExpert Review of Molecular Diagnostics
Vol/bind18
Udgave nummer5
Sider (fra-til)423-431
Antal sider9
ISSN1473-7159
DOI
StatusUdgivet - maj 2018

ID: 55401044